Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...
Optum notable drugs nearing FDA approval include Anaphylm, Sotyktu, and insulin icodec with decisions expected early 2026.
Treatments for are allergic fungal rhinosinusitis, bipolar I disorder, Hunter syndrome, Leber hereditary optic neuropathy, ovarian cancer, and schizophrenia under review.
Stocktwits on MSN
Disc Medicine, Sanofi, Eli Lilly shares slip on reports of FDA increasing review time for drugs granted priority review vouchers
FDA is slated to decide on Disc Medicine's Bitopertin by February. ・Approval for Lilly’s obesity pill is expected by April 10 ...
Eli Lilly (LLY) shares slipped ~5% on Thursday, marking what could be its biggest intraday loss in five months after Reuters ...
After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after ...
Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is starting the new year with its first ...
Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on ...
The Food and Drug Administration has approved Nereus (tradipitant) for the prevention of vomiting induced by motion in adults.
Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback